Publications by authors named "Markus Gastpar"

Claim this Profile
W
What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial.
Rebecca Schennach, Michael Riedel, Michael Obermeier, Markus Jäger, Max Schmauss, Markus Gastpar

Eur Arch Psychiatry Clin Neurosci· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients.
Pierre Baumann, Chin B Eap, Markus Gastpar

Basic Clin Pharmacol Toxicol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission in schizophrenia - What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression.
Rebecca Schennach, Michael Obermeier, Ilja Spellmann, Florian Seemüller, Richard Musil, Markus Gastpar

Schizophr Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How?
Rebecca Schennach, Michael Obermeier, Florian Seemüller, Markus Jäger, Max Schmauss, Markus Gastpar

Pharmacopsychiatry· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies.
Ilja Spellmann, Rebecca Schennach, Florian Seemüller, Sebastian Meyer, Richard Musil, Markus Gastpar

Eur Arch Psychiatry Clin Neurosci· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods.
Rebecca Schennach, Hans-Jürgen Möller, Michael Obermeier, Florian Seemüller, Markus Jäger, Markus Gastpar

Int J Methods Psychiatr Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.
Rebecca Schennach, Michael Riedel, Michael Obermeier, Ilja Spellmann, Richard Musil, Markus Gastpar

Eur Arch Psychiatry Clin Neurosci· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.
Siegfried Kasper, Markus Gastpar, Walter E Müller, Hans-Peter Volz, Hans-Jürgen Möller

Int J Neuropsychopharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypericum extract WS ® 5570 for depression--an overview.
Markus Gastpar

Int J Psychiatry Clin Pract· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale.
Rebecca Schennach, Michael Obermeier, Florian Seemüller, Markus Jäger, Max Schmauss, Markus Gastpar

Psychopathology· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-year functional outcomes of naturalistically treated patients with schizophrenia.
Ilja Spellmann, Michael Riedel, Rebecca Schennach, Felix Seemüller, Michael Obermeier, Markus Gastpar

Psychiatry Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response trajectories in "real-world" naturalistically treated schizophrenia patients.
Rebecca Schennach, Sebastian Meyer, Florian Seemüller, Markus Jäger, Max Schmauss, Markus Gastpar

Schizophr Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial.
Rebecca Schennach, Michael Riedel, Michael Obermeier, Markus Jäger, Max Schmauss, Markus Gastpar

Psychiatr Q· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
Michael Riedel, Andreas Mayr, Florian Seemüller, Wolfgang Maier, Stefan Klingberg, Markus Gastpar

World J Biol Psychiatry· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of relapse in the year after hospital discharge among patients with schizophrenia.
Rebecca Schennach, Michael Obermeier, Sebastian Meyer, Markus Jäger, Max Schmauss, Markus Gastpar

Psychiatr Serv· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
Rebecca Schennach-Wolff, Sebastian Meyer, Florian Seemüller, Markus Jäger, Max Schmauss, Markus Gastpar

J Psychiatr Res· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?
Rebecca Schennach-Wolff, Markus Jäger, Andreas Mayr, Sebastian Meyer, Kai-Uwe Kühn, Markus Gastpar

Eur Neuropsychopharmacol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study.
Rebecca Schennach-Wolff, Michael Obermeier, Florian Seemüller, Markus Jäger, Max Schmauss, Markus Gastpar

J Clin Psychopharmacol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.
Siegfried Kasper, Markus Gastpar, Walter E Müller, Hans-Peter Volz, Hans-Jürgen Möller

Wien Med Wochenschr· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial.
Siegfried Kasper, Markus Gastpar, Walter E Müller, Hans-Peter Volz, Hans-Jürgen Möller

Int Clin Psychopharmacol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?
Rebecca Schennach-Wolff, Markus Jäger, Michael Obermeier, Max Schmauss, Gerd Laux, Markus Gastpar

World J Biol Psychiatry· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression.
Siegfried Kasper, Markus Gastpar, Hans-Juergen Möller, Walter E Müller, Hans-Peter Volz

Int Clin Psychopharmacol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An early improvement threshold to predict response and remission in first-episode schizophrenia.
Rebecca Schennach-Wolff, Florian Hannes Seemüller, Andreas Mayr, Wolfgang Maier, Stefan Klingberg, Markus Gastpar

Br J Psychiatry· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical symptoms of major depression are associated with the intensity dependence of auditory event-related potential components.
Thomas Linka, Gudrun Sartory, Markus Gastpar, Norbert Scherbaum, Bernhard W Müller

Psychiatry Res· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis